BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Orme T, Guerreiro R, Bras J. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions. Curr Neurol Neurosci Rep 2018;18:67. [PMID: 30097731 DOI: 10.1007/s11910-018-0874-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 O’day DH. Calmodulin Binding Domains in Critical Risk Proteins Involved in Neurodegeneration. CIMB 2022;44:5802-5814. [DOI: 10.3390/cimb44110394] [Reference Citation Analysis]
2 Harerimana NV, Goate AM, Bowles KR. The influence of 17q21.31 and APOE genetic ancestry on neurodegenerative disease risk. Front Aging Neurosci 2022;14:1021918. [DOI: 10.3389/fnagi.2022.1021918] [Reference Citation Analysis]
3 Tábuas-pereira M, Guerreiro R, Kun-rodrigues C, Almeida MR, Brás J, Santana I. Whole-exome sequencing reveals PSEN1 and ATP7B combined variants as a possible cause of early-onset Lewy body dementia: a case study of genotype–phenotype correlation. Neurogenetics 2022. [DOI: 10.1007/s10048-022-00699-0] [Reference Citation Analysis]
4 Levy G, Levin B, Engelhardt E. Advancing the Genetics of Lewy Body Disorders with Disease‐Modifying Treatments in Mind. Advanced Genetics 2022. [DOI: 10.1002/ggn2.202200011] [Reference Citation Analysis]
5 Grycuk E, Eichenholtz E, Aarsland D, Betzhold S, Daly G, Folkerts A, Kalbe E, Kane JP, Kinchin I, Saldanha I, Smith V, Taylor J, Thompson R, Leroi I. Developing a core outcome set (COS) for Dementia with Lewy bodies (DLB). HRB Open Res 2022;5:57. [DOI: 10.12688/hrbopenres.13590.1] [Reference Citation Analysis]
6 M. Olichney J, Li W, Gharbaoui Y, P. Kwok A, E. Jenkins J. Diagnosis of Dementia with Lewy Bodies: Fluctuations, Biomarkers, and Beyond. Dementia in Parkinson’s Disease - Everything you Need to Know 2022. [DOI: 10.5772/intechopen.98433] [Reference Citation Analysis]
7 Srivastava A, Alam P, Caughey B. RT-QuIC and Related Assays for Detecting and Quantifying Prion-like Pathological Seeds of α-Synuclein. Biomolecules 2022;12:576. [DOI: 10.3390/biom12040576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gupta MK, Randhawa PK, Masternak MM. Role of BAG5 in Protein Quality Control: Double-Edged Sword? Front Aging 2022;3. [DOI: 10.3389/fragi.2022.844168] [Reference Citation Analysis]
9 Strempfl K, Unger MS, Flunkert S, Trost A, Reitsamer HA, Hutter-paier B, Aigner L. Leukotriene Signaling as a Target in α-Synucleinopathies. Biomolecules 2022;12:346. [DOI: 10.3390/biom12030346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pitman J, Chiang GC. Dementia with Lewy Bodies. Hybrid PET/MR Neuroimaging 2022. [DOI: 10.1007/978-3-030-82367-2_25] [Reference Citation Analysis]
11 Jo S, Park KW, Hwang YS, Lee SH, Ryu HS, Chung SJ. Microarray Genotyping Identifies New Loci Associated with Dementia in Parkinson's Disease. Genes (Basel) 2021;12:1975. [PMID: 34946922 DOI: 10.3390/genes12121975] [Reference Citation Analysis]
12 Upadhyay A. Natural compounds in the regulation of proteostatic pathways: An invincible artillery against stress, ageing, and diseases. Acta Pharm Sin B 2021;11:2995-3014. [PMID: 34729300 DOI: 10.1016/j.apsb.2021.01.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
13 D'Antonio F, Kane JPM, Ibañez A, Lewis SJG, Camicioli R, Wang H, Yu Y, Zhang J, Ji Y, Borda MG, Kandadai RM, Babiloni C, Bonanni L, Ikeda M, Boeve BF, Leverenz JB, Aarsland D; ISTAART Lewy body dementias Consortia Working Group. Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimers Dement (Amst) 2021;13:e12235. [PMID: 34541289 DOI: 10.1002/dad2.12235] [Reference Citation Analysis]
14 Bono AD, Twaite JT, Krch D, McCabe DL, Scorpio KA, Stafford RJ, Borod JC. Mood and emotional disorders associated with parkinsonism, Huntington disease, and other movement disorders. Handb Clin Neurol 2021;183:175-96. [PMID: 34389117 DOI: 10.1016/B978-0-12-822290-4.00015-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hoppe SO, Uzunoğlu G, Nussbaum-Krammer C. α-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies? Biomolecules 2021;11:931. [PMID: 34201558 DOI: 10.3390/biom11070931] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
16 Goldstein O, Gana-Weisz M, Shiner T, Attar R, Mordechai Y, Waldman YY, Bar-Shira A, Thaler A, Gurevich T, Mirelman A, Giladi N, Orr-Urtreger A. R869C mutation in molecular motor KIF17 gene is involved in dementia with Lewy bodies. Alzheimers Dement (Amst) 2021;13:e12143. [PMID: 34124335 DOI: 10.1002/dad2.12143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kowalska M, Wize K, Prendecki M, Lianeri M, Kozubski W, Dorszewska J. Genetic Variants and Oxidative Stress in Alzheimer's Disease. Curr Alzheimer Res 2020;17:208-23. [PMID: 32091332 DOI: 10.2174/1567205017666200224121447] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
18 Vergouw LJM, Bosman B, van de Beek M, Salomé M, Hoogers SE, van Steenoven I, Roks G, Bonifati V, van Swieten JC, Lemstra AW, de Jong FJ. Family History is Associated with Phenotype in Dementia with Lewy Bodies. J Alzheimers Dis 2020;73:269-75. [PMID: 31771063 DOI: 10.3233/JAD-190825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Combi R, Salsone M, Villa C, Ferini-Strambi L. Genetic Architecture and Molecular, Imaging and Prodromic Markers in Dementia with Lewy Bodies: State of the Art, Opportunities and Challenges. Int J Mol Sci 2021;22:3960. [PMID: 33921279 DOI: 10.3390/ijms22083960] [Reference Citation Analysis]
20 Koziorowski D, Figura M, Milanowski ŁM, Szlufik S, Alster P, Madetko N, Friedman A. Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences. Cells 2021;10:656. [PMID: 33809527 DOI: 10.3390/cells10030656] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
21 Saracino D, Le Ber I. Clinical Update on C9orf72: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Beyond. Adv Exp Med Biol 2021;1281:67-76. [PMID: 33433869 DOI: 10.1007/978-3-030-51140-1_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
22 Lee JY, Marian OC, Don AS. Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. Neuromolecular Med 2021;23:1-24. [PMID: 33550528 DOI: 10.1007/s12017-021-08644-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Upadhyay A, Sundaria N, Dhiman R, Prajapati VK, Prasad A, Mishra A. Complex Inclusion Bodies and Defective Proteome Hubs in Neurodegenerative Disease: New Clues, New Challenges. Neuroscientist 2021;:1073858421989582. [PMID: 33530848 DOI: 10.1177/1073858421989582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Jeon YM, Kwon Y, Jo M, Lee S, Kim S, Kim HJ. The Role of Glial Mitochondria in α-Synuclein Toxicity. Front Cell Dev Biol 2020;8:548283. [PMID: 33262983 DOI: 10.3389/fcell.2020.548283] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Melland H, Carr EM, Gordon SL. Disorders of synaptic vesicle fusion machinery. J Neurochem 2021;157:130-64. [PMID: 32916768 DOI: 10.1111/jnc.15181] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
26 Heras-Garvin A, Stefanova N. From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein. Front Synaptic Neurosci 2020;12:584536. [PMID: 33071772 DOI: 10.3389/fnsyn.2020.584536] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
27 Levy G, Levin B, Engelhardt E. The Nosology of Lewy Body Disorders From Analytic-Epidemiologic and Statistical Vantage Points. Mov Disord 2020;35:2156-61. [PMID: 32936973 DOI: 10.1002/mds.28288] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Fouka M, Mavroeidi P, Tsaka G, Xilouri M. In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons. Front Cell Dev Biol 2020;8:559791. [PMID: 33015057 DOI: 10.3389/fcell.2020.559791] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
29 Macbean LF, Smith AR, Lunnon K. Exploring Beyond the DNA Sequence: A Review of Epigenomic Studies of DNA and Histone Modifications in Dementia. Curr Genet Med Rep 2020;8:79-92. [DOI: 10.1007/s40142-020-00190-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
30 Urbizu A, Beyer K. Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy. Int J Mol Sci 2020;21:E4718. [PMID: 32630630 DOI: 10.3390/ijms21134718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
31 Kovalev SS, Dergilev AI, Orlov YL, Fateev OD, Kavai-ool UN. Reconstruction of Dementia Gene Network Using Online Bioinformatics Tools. 2020 Cognitive Sciences, Genomics and Bioinformatics (CSGB) 2020. [DOI: 10.1109/csgb51356.2020.9214618] [Reference Citation Analysis]
32 Martin S, Smolders S, Van den Haute C, Heeman B, van Veen S, Crosiers D, Beletchi I, Verstraeten A, Gossye H, Gelders G, Pals P, Hamouda NN, Engelborghs S, Martin JJ, Eggermont J, De Deyn PP, Cras P, Baekelandt V, Vangheluwe P, Van Broeckhoven C; BELNEU consortium. Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathol 2020;139:1001-24. [PMID: 32172343 DOI: 10.1007/s00401-020-02145-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
33 Guerreiro R, Gibbons E, Tábuas-Pereira M, Kun-Rodrigues C, Santo GC, Bras J. Genetic architecture of common non-Alzheimer's disease dementias. Neurobiol Dis 2020;142:104946. [PMID: 32439597 DOI: 10.1016/j.nbd.2020.104946] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
34 Chouliaras L, Kumar GS, Thomas AJ, Lunnon K, Chinnery PF, O'Brien JT. Epigenetic regulation in the pathophysiology of Lewy body dementia. Prog Neurobiol 2020;192:101822. [PMID: 32407744 DOI: 10.1016/j.pneurobio.2020.101822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Cochran JN, Geier EG, Bonham LW, Newberry JS, Amaral MD, Thompson ML, Lasseigne BN, Karydas AM, Roberson ED, Cooper GM, Rabinovici GD, Miller BL, Myers RM, Yokoyama JS; Alzheimer’s Disease Neuroimaging Initiative. Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases. Am J Hum Genet 2020;106:632-45. [PMID: 32330418 DOI: 10.1016/j.ajhg.2020.03.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
36 Smolders S, Van Broeckhoven C. Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson's disease pathogenesis. Acta Neuropathol Commun 2020;8:63. [PMID: 32375870 DOI: 10.1186/s40478-020-00935-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 16.5] [Reference Citation Analysis]
37 Koga S, Li F, Zhao N, Roemer SF, Ferman TJ, Wernick AI, Walton RL, Faroqi AH, Graff-Radford NR, Cheshire WP, Ross OA, Dickson DW. Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. Brain Pathol 2020;30:766-78. [PMID: 32232888 DOI: 10.1111/bpa.12839] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
38 Brás IC, Dominguez-Meijide A, Gerhardt E, Koss D, Lázaro DF, Santos PI, Vasili E, Xylaki M, Outeiro TF. Synucleinopathies: Where we are and where we need to go. J Neurochem 2020;153:433-54. [PMID: 31957016 DOI: 10.1111/jnc.14965] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 22.0] [Reference Citation Analysis]
39 Jiao B, Zhou L, Zhou Y, Weng L, Liao X, Tian Y, Guo L, Liu X, Yuan Z, Xiao X, Jiang Y, Wang X, Yang Q, Li C, Zhu Y, Zhou L, Zhang W, Wang J, Li Y, Gu W, Yang J, Xia J, Huang Q, Yin J, Xue J, Duan R, Tang B, Shen L. Identification of expanded repeats in NOTCH2NLC in neurodegenerative dementias. Neurobiol Aging 2020; 89: 142.e1-142. e7. [PMID: 32081467 DOI: 10.1016/j.neurobiolaging.2020.01.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 18.5] [Reference Citation Analysis]
40 Bernal-Conde LD, Ramos-Acevedo R, Reyes-Hernández MA, Balbuena-Olvera AJ, Morales-Moreno ID, Argüero-Sánchez R, Schüle B, Guerra-Crespo M. Alpha-Synuclein Physiology and Pathology: A Perspective on Cellular Structures and Organelles. Front Neurosci 2019;13:1399. [PMID: 32038126 DOI: 10.3389/fnins.2019.01399] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
41 Goldman J, Fahn S. Parkinson disease and related disorders. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease 2020. [DOI: 10.1016/b978-0-12-813866-3.00002-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Singh B, Covelo A, Martell-Martínez H, Nanclares C, Sherman MA, Okematti E, Meints J, Teravskis PJ, Gallardo C, Savonenko AV, Benneyworth MA, Lesné SE, Liao D, Araque A, Lee MK. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy. Acta Neuropathol 2019;138:551-74. [PMID: 31168644 DOI: 10.1007/s00401-019-02032-w] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
43 Hammond TR, Marsh SE, Stevens B. Immune Signaling in Neurodegeneration. Immunity 2019;50:955-74. [PMID: 30995509 DOI: 10.1016/j.immuni.2019.03.016] [Cited by in Crossref: 129] [Cited by in F6Publishing: 101] [Article Influence: 43.0] [Reference Citation Analysis]
44 Cochran JN, Geier EG, Bonham LW, Scott Newberry J, Amaral MD, Thompson ML, Lasseigne BN, Karydas AM, Roberson ED, Cooper GM, Rabinovici GD, Miller BL, Myers RM, Yokoyama JS. Non-Coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases.. [DOI: 10.1101/759621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, Allan LM, Thomas AJ, O'Brien JT. New evidence on the management of Lewy body dementia.Lancet Neurol. 2020;19:157-169. [PMID: 31519472 DOI: 10.1016/S1474-4422(19)30153-X] [Cited by in Crossref: 83] [Cited by in F6Publishing: 63] [Article Influence: 27.7] [Reference Citation Analysis]
46 Vitanova KS, Stringer KM, Benitez DP, Brenton J, Cummings DM. Dementia associated with disorders of the basal ganglia. J Neurosci Res 2019;97:1728-41. [PMID: 31392765 DOI: 10.1002/jnr.24508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
47 Heckman MG, Kasanuki K, Brennan RR, Labbé C, Vargas ER, Soto AI, Murray ME, Koga S, Dickson DW, Ross OA. Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease. Mov Disord 2019;34:1325-32. [PMID: 31234228 DOI: 10.1002/mds.27773] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
48 Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna) 2019;126:933-95. [PMID: 31214855 DOI: 10.1007/s00702-019-02028-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
49 Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions. J Neurochem 2019;150:467-74. [PMID: 30892688 DOI: 10.1111/jnc.14698] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 17.3] [Reference Citation Analysis]
50 Lin YW, Truong D. Diffuse Lewy body disease. J Neurol Sci 2019;399:144-50. [PMID: 30807982 DOI: 10.1016/j.jns.2019.02.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Doi H, Sakakibara R, Masuda M, Tateno F, Aiba Y, Kishi M, Yamanishi T, Yamamoto T, Matsuoka K. Gastrointestinal function in dementia with Lewy bodies: a comparison with Parkinson disease. Clin Auton Res 2019;29:633-8. [PMID: 30741396 DOI: 10.1007/s10286-019-00597-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
52 Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor JP, Thomas A, Attems J, McKeith I. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener 2019;14:5. [PMID: 30665447 DOI: 10.1186/s13024-019-0306-8] [Cited by in Crossref: 125] [Cited by in F6Publishing: 129] [Article Influence: 41.7] [Reference Citation Analysis]